Ambu A/S

This is a friendly reminder to secure your seat for in-person attendance at Ambu’s Capital Markets Day, taking place on 1 October 2025 from 10:00 to 16:30 CEST at our headquarters in Denmark, Baltorpbakken 13, 2750 Ballerup. We look forward to welcoming institutional investors, analysts, and financial media for a day of insights on strategy and market opportunities. Furthermore, it is an opportunity to meet with the broader Executive Leadership Team, as well as key external speakers. Finally, there will be a product demonstration at the end of the event, offering participants the opportunity to experience Ambu’s solutions firsthand. All presentations and Q&As are held from 10:00-15:00 CEST. The presentations will be held in English, and they will be recorded. After the event, the recorded presentations and the presentation materials will be published on Ambu’s website. The product demonstration will run from 15:00-16:30 CEST and will be for in-person attendees only. SIGN UP FOR IN-PERS

Steven Block steps down; Scott Heinzelman appointed as new President to drive Ambu’s strong growth trajectory in North America.

Ambu invites institutional investors, analysts, and financial media to the company’s Capital Markets Day on Wednesday 1 October 2025.

The FDA clearance for the Ambu® aScope™ 5 Cysto HD marks a historic milestone as the first ever single-use cysto-nephroscope to receive such clearance in the US. It follows the CE mark in Europe earlier this year, representing an important step forward in endoscopic technology and reinforcing Ambu’s commitment to innovation and advancement in urology care.

Today, Ambu announces the launch of its new Ambu® Recircle program, teaming up with hospitals in both the US and the UK as the first key participants.

Ambu has expanded its newly launched Ambu® SureSight™ Connect video laryngoscopy solution with the introduction of five new blades designed specifically for paediatric patients.

Jesper Johnsen Steen has been appointed as Ambu’s new Chief Marketing Officer, effective 1 May 2025.

With the CE mark expansion for Ambu® aScope™ 5 Cysto HD, urologists will now be able to use the medical technology as a single-use flexible cysto-nephroscopy solution, reflecting Ambu’s commitment to addressing a growing range of urology needs for patients and healthcare professionals.

With the launch of the Ambu® SureSight™ Connect solution, Ambu offers clinicians the only airway visualisation and pulmonology offering that features a one-lung ventilation solution and includes all the devices recommended for intubation and airway assessment.

Following the FDA clearance for the Ambu® aScope™ 5 Cysto HD solution, Ambu introduces its HD cystoscope to urologists in the USA, expanding the urology offering and meeting advanced needs for cystoscopy procedures requiring superior image quality.

Having obtained both CE mark and FDA clearance, Ambu continues its controlled market release phase, focused on evaluation in key hospitals in the USA and Europe.

The new clearance marks Ambu’s rapidly growing presence in urology, advancing the company’s urology portfolio in the U.S. market.

Henrik Birk steps down from his position as Chief Operations Officer at Ambu. Former Novozymes COO, Graziela Malucelli, takes on the position, effective immediately.

To meet the unique needs of gastroenterologists performing ERCP procedures, Ambu’s new generation aScope Duodeno 2 solution constitutes a step change from previous generations, driven by valuable collaboration with healthcare professionals.

Ambu’s aScope™ Gastro Large, with its 4.2 mm working channel and endoscope handle made with bioplastics, expands the company’s single-use portfolio for upper gastroenterology (GI) procedures. The expanded portfolio allows physicians to address an extended range of needs across the ICU, OR and endoscopy suite.